Cosmos Holdings Just Joined

The Nasdaq Capital Market

Could this Company Become a Major Disruptor in an

Estimated $1.3 Trillion Global Pharma Industry?



NASDAQ: COSM

Build your watchlist with us

Get the latest stock ideas direct to your inbox. 100% free and your information stays with us.

7 Reasons to Consider Cosmos Holdings - NASDAQ: COSM

A recent uplisting to the NASDAQ Capital Market will bring significantly more exposure and visibility to Cosmos in the near term.
The company’s Greece located pharmaceutical logistic center, CosmoFarm, just got a major facelift with the integration of an SSI SCHAEFER’s A-Frame Automated Robotic Picking System.


According to Fortune Business Insights, the health scare in 2020 “accelerated the demand for effective treatments and dr-ugs worldwide” and caused the global pharmaceutical industry to reach an estimated valuation of $1.3 Trillion. (2)
Cosmos has an extensive network of over 160 clients and vendors in Germany, the United Kingdom, United Arab Emirates, Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, Netherlands, and Greece.
The foundation of Cosmos’ operating strategy is the optimization and growth of its pharmaceutical sourcing and distribution businesses. On the other hand, its sourcing and distribution, including specialty pharmaceuticals, is what Cosmos sees as the anchor of its development and position in the pharmaceutical supply channel.
Not only did Cosmos see 2020 revenue growth of about 40% and jaw-dropping gross profit growth of nearly 120%,(9) it reported 15.8% year-over-year growth and a 27.8% sequential increase in revenue for Q2 2021. (1)
Cosmos just secured a major investment from Ault Global Holdings for about $5.5 million. Ault Global’s Executive Chairman, Milton “Todd” Ault, III, said, “We are delighted to make this strategic investment in Cosmos given their scalable business model and significant market opportunity. We believe this investment will help accelerate the growth of their business.” (5)

The Global Health Scare

The health scare has only accelerated the global demand for medication.


In fact, according to Fortune Business Insights, in 2020, the health scare “accelerated the demand for effective treatments and drugs worldwide” and caused the global pharmaceutical industry to reach an estimated valuation of $1.3 Trillion.(2)

In addition, they noted there’s an “increasing prevalence of chronic disease and the growing adoption of modern technologies that are leading to the evolving pharmaceuticals sector.”

This is why Fortune believes we could see the global pharmaceuticals market size reach nearly $2.15 trillion by 2027 at an estimated CAGR of 7.0%.(3)

Where Cosmos Holdings (NASDAQ: COSM) Fits


One of the top companies benefiting from this pharma rush is Cosmos Holdings (NASDAQ COSM). Cosmos is a disruptive company that offers customers and shareholders diversified exposure to several in-demand and growing verticals in the pharma and wellness space, including:(4)

  • Branded Pharmaceuticals
  • Generic Pharmaceuticals
  • Health Products & Food Supplements
  • Research & Development
  • Acquisitions
  • Green leaf derived products
  • Local & Direct to Pharmacy Wholesale

Clearly, Cosmos and its unique business model may be doing something right.

Not only did Cosmos see 2020 revenue growth of about 40% and jaw-dropping gross profit growth of nearly 120%,(9) it reported 15.8% year-over-year growth and a 27.8% sequential increase in revenue for Q2 2021.(1)

But that’s not the company’s biggest news at the moment…

In a major company milestone, Cosmos just uplisted to the Nasdaq Capital Market!(10)


Why is this so huge? Easy. When a company uplists to a major exchange, there typically comes a significant amount of added visibility and exposure for them to bask in.


Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated,

"We are very excited to announce our listing on Nasdaq, which is a major milestone to drive further opportunities to scale our business and expand our distribution network worldwide for our proprietary lines of nutraceuticals as well as third-party branded pharmaceuticals.”(10)

The best part of all of this? It may only be the start of more game-changing company developments to come…

So Just Who is Cosmos Holdings Exactly?

Cosmos Holdings Inc. is a fully reporting Pharmaceutical Holding Company based in Chicago, Illinois, USA, that specializes, through its subsidiaries, in the wholesale of pharmaceutical products throughout Europe.

The company is focused on identifying, acquiring, developing, and commercializing different medicines to improve patients’ lives. Cosmos has an extensive network of over 160 clients and vendors in Germany, the United Kingdom, United Arab Emirates, Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, Netherlands, and Greece.(8) Not to mention, Cosmos has offices and distribution centers in Thessaloniki, Greece, and Harlow, UK.(8)


Even more impressive is how quickly the company is growing. On top of the company’s massive earnings growth, CEO Greg Siokas recently said:

“We are rapidly expanding our distribution network worldwide and opening new markets for our proprietary line of branded pharmaceuticals, nutraceuticals, and food supplements.

We entered into an exclusive distribution agreement with Mediprovita GbR (Mediprovita) for the distribution of our full line of proprietary nutraceuticals, Sky Premium Life, in Germany and Austria. Mediprovita has over 25 years of expertise in e-commerce and a successful track record in selling health products.” (1)

Additionally, the company “entered into a three-year distribution agreement with China-based REMAI e-Commerce Co., Ltd. (REMAI) to open a flagship store and launch our Sky Premium Life products on Alibaba’s Tmall Global, the world’s largest cross-border e-commerce marketplace with 500 million monthly active users.”(1)

Plus, according to the CEO, over the past three months, Cosmos began reducing its debt and has now converted $5.25 million of it to equity.(1)

Cosmos Holdings: Invests in Advanced Technologies to Expand Productivity (11)

A few months back, Cosmos made a HUGE announcement in regards to installing a “State-of-the-Art” automated fulfillment system at their logistics center in Greece.


The fully automated fulfillment system is designed to process complex orders with precision and speed, leading to increased performance while drastically lowering error rates.


The system can process up to 40,000 products per hour and can accommodate a variety of packaging shapes and sizes.

Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated,

“With a fully robotic system in place, CosmoFarm’s logistic center can now process orders at higher speeds and higher quality, even at peak times. This is critical to maintain the quality of our service while scaling our product offerings and client base. This installation reflects our commitment to invest in advanced technologies that substantially expand our current productivity and throughput, supporting our growth and improving the overall efficacy of our deliverables.” (11)

CosmoFarm, headquartered in Athens, Greece is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. CosmoFarm’s core activity is sourcing, procuring, and distributing branded and generic medicines, over-the-counter (OTC) pharmaceuticals, food supplements, and medical devices to its growing network of more than 1,130 pharmacies.

Now, to the Bread and Butter: Cosmos Holdings Has a Comprehensive Strategy

The foundation of Cosmos’ operating strategy is the optimization and growth of its pharmaceutical sourcing and distribution businesses. As Cosmos continues devoting significant resources to improve its operating and capital efficiencies, it believes it’s well-positioned in size and breadth to continue growing its trading businesses.

Sourcing and distribution, including specialty pharmaceuticals, is what Cosmos sees as the anchor of its growth and position in the pharmaceutical supply channel. Cosmos provides superior services and delivers value-added products, which improve the efficiency and competitiveness of healthcare providers. In turn, this aids the pharmaceutical supply channel to better provide healthcare to patients.

Get the latest stock ideas direct to your inbox.

100% free and your information stays with us.

Specific areas of Cosmos (NASDAQ: COSM) focus include the following: (7)

  1. Branded Pharmaceuticals: Branded pharmaceutical products are the primary product category that Cosmos imports and exports. To maximize its performance, Cosmos evaluates product availability, pricing, demand trends, and patent expirations. As the patents for branded products near expiration, the generic equivalents enter the marketplace. Thus, demand for those branded products starts to decrease. Cosmos monitors these cycles closely and always looks to find value in pricing fluctuations caused by the patent expirations as the generic equivalents enter the market.
  2. Generic Pharmaceuticals: Generic pharmaceutical products are the secondary product category that Cosmos imports and exports. The company applies the same discipline to generics that it does with the branded. Just as with branded products, Cosmos is continuously evaluating the supply/demand as patents expire. This insight sheds light on the demand for generic products that take their place. Understanding the historical and market-specific characteristics of generic product demand provides insight that Cosmos uses to guide its vendors that source its generic drug exports.
  3. Health Products & Food Supplements: The wholesale distribution of food supplements actually offer more significant margins than pharmaceutical product distribution. Cosmos is always looking to expand the portfolio of products that we distribute to maximize our margins. It also conveniences Cosmos’ customer base by providing them a more extensive portfolio of products that they can source from a single vendor.
  4. Research & Development: Cosmos is committed to strategic R&D across each business unit with a particular focus on nutraceutical products with inherently lower risk profiles and clearly defined regulatory pathways. The company constantly evaluates the demand for food supplements in the markets where it currently distributes pharmaceutical products. This research and analysis determines which food and nutritional supplements Cosmos chooses to develop and their formulations. This approach aims to maximize the probability of successfully competing with other brands in the marketplace.
  5. Acquisitions: Cosmos regularly evaluates acquisition targets that could expand its distribution reach and/or vertically integrate into the supply chain of the products that it currently distributes. In addition to focusing on organic growth drivers, the company is actively pursuing accretive acquisitions. It focuses on those offering long-term revenue growth, margin expansion through synergies, and the ability to maintain a flexible capital structure.
  6. Green Leaf-derived products: Cosmos closely monitors the legal framework for prescription and nonprescription derivatives of green leaf products as it develops in Europe. As the legal framework and processes are developed and implemented in each respective EU country, Cosmos plans to utilize its existing network to distribute both prescription and nonprescription derivatives of green leaf products to its current customer base. For the time being, Cosmos currently intends to only distribute prescription and nonprescription derivatives of green leaf products to approved EU countries and not in the US.
  7. Local & Direct to Pharmacy Wholesale: Cosmos is also expanding into the full-line wholesale distribution business through acquisitions. Full-line pharmaceutical wholesalers provide the local markets with branded pharmaceuticals, generic pharmaceuticals, over-the-counter (OTC) medicines, vitamins, and food supplements. By expanding its pharmaceutical distribution business, Cosmos believes that it will have a better ability to directly source more branded and generic products from manufacturers. That way, Cosmos can potentially sell its vitamins, food supplements, and cosmetic products directly to pharmacies for better prices. This expansion expects to increase its sales and profit margins as it vertically integrates into the supply chain.

Cosmos is Also Very Well Known for the Following 3 Subsidiaries Under its Belt: (8)

Sky Pharm SA:

Sky Pharm SA is a Thessaloniki, Greece-based pharmaceutical trading firm. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. Cosmos buys from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers and then exports them to European markets where demand and prices are substantially higher.

DHNDecahedron Ltd.:

Decahedron Ltd. is a UK-incorporated pharmaceutical wholesaler. It is audited by the MHRA under European GDP (Good Distribution Practices). It is also a full member of the EAEPC and has been audited by TÜV on its behalf. Decahedron imports and exports branded, generic and unlicensed POM, OTCs, and medical devices worldwide. It also participates in governmental tenders and registers dossiers in new territories. This subsidiary’s network consists of roughly 25 clients and vendors expanding to 9 countries, including Germany, UK, Denmark, United Arab Emirates, Germany, Italy, France, Singapore, and Ireland.

Cosmofarm:

Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area.

Sources

Source 1:https://www.cosmosholdingsinc.com/investors/press-releases/93-cosmos-holdings-reports-15-8-year-over-year-growth-and-27-8-sequential-increase-in-revenue-for-the-second-quarter-of-2021

Source 2: https://bit.ly/3sTk48z

Source 3: https://bit.ly/3vnYLh4

Source 4: https://www.cosmosholdingsinc.com/company/strategy

Source 5: https://finance.yahoo.com/news/cosmos-holdings-secures-approximately-5-131500199.html

Source 6: https://www.barchart.com/stocks/quotes/COSM/interactive-chart

Source 7: https://www.cosmosholdingsinc.com/company/strategy

Source 8: https://www.cosmosholdingsinc.com

Source 9: https://www.globenewswire.com/en/news-release/2021/04/16/2211656/0/en/Cosmos-Holdings-Reports-Revenue-Growth-of-40-to-a-Record-55-4-Million-and-Achieves-Profitability-for-2020.html

Source 10: https://finance.yahoo.com/news/exchange-listing-client-cosmos-holdings-130000890.html

Source 11: https://finance.yahoo.com/news/cosmos-holdings-announces-installation-state-141100752.html

Disclaimer

Stock Research Today is a project of Dadmin Capital LLC and intended solely for entertainment and informational purposes. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/. This website / media webpage is owned, operated and edited by Dadmin Capital LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Dadmin Capital” refers to Dadmin Capital LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage .We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Dadmin Capital business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Dadmin Capital. often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Compensation – Pursuant to an agreement between Dadmin Capital LLC and TD Media LLC, Dadmin Capital LLC has been hired for a period beginning on 3/23/22 and ending after 2 business days to publicly disseminate information about (NASDAQ: COSM) via digital communications. We have been paid eleven thousand five hundred USD via ACH Bank Transfer.